GHRS Stock Overview
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$17.19|
|52 Week High||US$30.43|
|52 Week Low||US$12.38|
|1 Month Change||-27.50%|
|3 Month Change||18.55%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-10.70%|
Recent News & Updates
We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry
The WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June. Investing in biotech may be the way to go for investors looking for large gains over the long term.
|GHRS||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how GHRS performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how GHRS performed against the US Market.
|GHRS Average Weekly Movement||17.4%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: GHRS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: GHRS's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD.
GH Research Fundamentals Summary
|GHRS fundamental statistics|
Is GHRS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GHRS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.10|
|Net Profit Margin||0.00%|
How did GHRS perform over the long term?See historical performance and comparison
Is GH Research undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GHRS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GHRS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GHRS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: GHRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GHRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GHRS is overvalued based on its PB Ratio (3.2x) compared to the US Pharmaceuticals industry average (2.1x).
How is GH Research forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GHRS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GHRS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GHRS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GHRS is forecast to have no revenue next year.
High Growth Revenue: GHRS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GHRS is forecast to be unprofitable in 3 years.
How has GH Research performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: GHRS is currently unprofitable.
Growing Profit Margin: GHRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GHRS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GHRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GHRS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: GHRS has a negative Return on Equity (-1.92%), as it is currently unprofitable.
How is GH Research's financial position?
Financial Position Analysis
Short Term Liabilities: GHRS's short term assets ($285.6M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: GHRS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: GHRS is debt free.
Reducing Debt: GHRS has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GHRS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GHRS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 144.8% each year
What is GH Research current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GHRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GHRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GHRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GHRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GHRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Theis Terwey (44 yo)
Mr. Theis Terwey, MD, PD, Dr. Med, is Chief Executive Officer at GH Research PLC since May 2021. He co-founded GH Research PLC in 2018 and was its Director from 2018 to 2020. Mr. Terwey also serves as a Se...
Experienced Board: GHRS's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: GHRS only recently listed within the past 12 months.
GH Research PLC's employee growth, exchange listings and data sources
- Name: GH Research PLC
- Ticker: GHRS
- Exchange: NasdaqGM
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$894.238m
- Shares outstanding: 52.02m
- Website: https://www.ghres.com
Number of Employees
- GH Research PLC
- 28 Baggot Street Lower
- Dublin 2
- Co. Dublin
- D02 NX43
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/22 23:15|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.